PepGen Inc.
$1.73
▼
-0.57%
2026-04-21 08:48:01
www.pepgen.com
NMS: PEPG
Explore PepGen Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$117.5 M
Current Price
$1.73
52W High / Low
$7.8 / $1.01
Stock P/E
—
Book Value
$2.14
Dividend Yield
—
ROCE
-58.05%
ROE
-67.39%
Face Value
—
EPS
$-2.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
56
Beta
2.34
Debt / Equity
11.53
Current Ratio
11.94
Quick Ratio
11.94
Forward P/E
-1.41
Price / Sales
—
Enterprise Value
$-18.1 M
EV / EBITDA
0.2
EV / Revenue
—
Rating
Strong Buy
Target Price
$10.29
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
| 2. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 3. | Moderna, Inc. | $55.11 | — | $21.94 B | — | -29.7% | -28.87% | $59.55 / $22.28 | $21.95 |
| 4. | Damora Therapeutics, Inc. | $26.43 | — | $1.6 B | — | -87.69% | -1.64% | $29.22 / $16.5 | $-110.11 |
| 5. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 6. | Lixte Biotechnology Holdings, Inc. | $3.44 | — | $39.91 M | — | -431.9% | -1.02% | $6.26 / $0.64 | $0.9 |
| 7. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.7 M | -18.65 M | -23.93 M | -31.32 M | -24.34 M |
| Net Profit | -18.34 M | -18.03 M | -23.09 M | -30.2 M | -22.24 M |
| EPS in Rs | -0.27 | -0.26 | -0.33 | -0.44 | -0.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -93.61 M | -97.74 M | -84.77 M | -68.3 M |
| Net Profit | -89.66 M | -89.98 M | -78.63 M | -69.1 M |
| EPS in Rs | -1.3 | -1.3 | -1.14 | -1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 173.91 M | 150.88 M | 143.05 M | 217.44 M |
| Total Liabilities | 26.46 M | 32.26 M | 34.63 M | 37.81 M |
| Equity | 147.44 M | 118.62 M | 108.42 M | 179.63 M |
| Current Assets | 150.96 M | 123.76 M | 112.68 M | 186.08 M |
| Current Liabilities | 12.65 M | 16.7 M | 17.53 M | 18.83 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -81.64 M | -82.37 M | -69 M | -59.27 M |
| Investing CF | -15.23 M | -37.67 M | -32 M | -3.75 M |
| Financing CF | 107.98 M | 88.75 M | -0.19 M | 112.19 M |
| Free CF | -81.9 M | -82.87 M | -71.6 M | -63.02 M |
| Capex | -0.26 M | -0.5 M | -2.6 M | -3.75 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -14.44% | -13.78% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.